Biopharma, a biopharmaceutical company, plans to launch the first phase of its plant for the production of pharmaceutical products and immunobiological preparations—which will provide a full cycle of blood plasma processing—in Uzhhorod in September. According to the Government Portal, the company has already invested EUR 67 million in construction. The total cost of the first phase is EUR 75 million.
Currently, the main building and the raw materials warehouse have been completed, and the equipment has been installed.
As previously reported, Biopharma had planned to launch the first phase of production in the first half of 2026.
According to the plan, the volume of blood plasma-derived drug production in Uzhhorod will be twice that of production in Bila Tserkva (Kyiv Oblast) and will reach up to 1.5 million liters per year.
Construction of the “Biopharma Plasma” plant in Uzhhorod began in the fall of 2024. The planned investment in the new facility is approximately EUR 80 million. The company’s Uzhhorod plant will focus on exports.
Biopharma exports its products to dozens of countries and plans to expand its presence in Europe, the Middle East, and Latin America, further increasing its capabilities.
